NEW YORK–(BUSINESS WIRE)–Elliptic, der weltweit führende Anbieter im Bereich On-Chain-Risiken, hat heute Pulse auf den Markt gebracht. Mit Pulse liegt die Priorisierung von Krypto-Hinweisen direkt in den Händen jedes Beamten an vorderster Front bei Strafverfolgungsbehörden und Behörden. Kryptowährungen betreffen mittlerweile jeden Bereich der Strafverfolgung – vom Streifenpolizisten auf der Straße bis hin zum Ermittler, der mit der Aufklärung eines Falles betraut ist. Pulse liefert jedem von
Month: September 2026
NOVA YORK–(BUSINESS WIRE)–A Elliptic, líder global em risco on-chain, lançou hoje o Pulse. O Pulse coloca a priorização de leads de criptomoedas diretamente nas mãos de cada autoridade governamental ou de aplicação da lei que atua na linha de frente. As criptomoedas agora afetam todas as áreas de aplicação da lei, de policiais nas ruas a detetives designados a investigar o caso. O Pulse dá a cada um deles um resumo financeiro rápido e preciso, e um ponto de partida: se é um endereço de cripto
What if measuring your pharmaceutical products’ environmental footprints could open doors that price alone never will? Clinical outcomes and cost have always decided whether a new pharmaceutical product — be it a vaccine, weight loss drug, or chemotherapy — reaches patients. That’s not going to change, nor should it. But lately, the institutions that decide which therapies make it to market are asking a new question: What impact does this therapy have on the environment? They want medicines built with raw materials that have a low environmental impact and that won’t become a regulatory liability in the future. They’re looking for therapies that leave less behind at end of life, and whose footprint a company can prove with data.
Including the environmental impact of therapies has never been a requirement, voluntary or mandatory, for market access bids, but this could be changing. For pharmaceutical companies ready to get ahead of that shift, a new standard for Life Cycle Assessments (LCAs) and Product Carbon Footprints (PCFs) is fast becoming one of the most powerful tools for winning market access.
Long considered the touchstone for measuring the environmental impacts of products as varied as food, furniture, concrete, and glass, LCAs give companies and their suppliers a clear, data-driven understanding of environmental hotspots across manufacturing and supply chains, while PCFs — an LCA focused solely on a product’s climate change impact — help companies drill down into their greenhouse gas (GHG) emissions. Yet despite their proven value elsewhere, the use of LCAs and PCFs in the pharmaceutical industry has never been standardized until now.
Introducing PAS 2090:2025, Pharmaceutical products – Product category rules for environmental life cycle assessments, the first internationally applicable framework for conducting both LCA and PCF assessments of pharmaceutical products. Here, we explore how PAS 2090-aligned LCAs and PCFs help pharma companies make sustainable decisions, reduce risk, and lead within a climate-conscious market.
Introduction of PAS 2090:2025
Released in November 2025, PAS 2090 reflects considerable cross-sector collaboration. The standard was developed by the British Standards Institution (BSI) with co-sponsorship from NHS England, the Office for Life Sciences (UK), and the Pharmaceutical LCA Consortium, using extensive global stakeholder input with insights from academia and healthcare. Over 475 stakeholders from 35 countries participated via a digital engagement hub, with more than 400 public comments submitted during the public consultation period.
In terms of functional specifications, PAS 2090 covers “pharmaceutical products intended for human use and the pharmaceutical product life cycle, including the drug substance, formulation, device (if applicable), packaging, distribution, patient use and end of product life.” It guides the process of assessing the environmental impact of pharmaceutical products from “cradle,” as in the sourcing of raw materials, up until the product’s final disposal, or “grave,” at end of life.
Though still in a nascent stage, the European Federation of Pharmaceutical Industries and Associations recognizes PAS 2090 as the “first publicly available specification to establish harmonized Product Category Rules (PCR) for conducting LCAs and PCFs of pharmaceutical products.” By adopting one unified standard, companies can generate aligned assessments without producing different analyses for each healthcare payer, thus reducing workload and improving trust in the data for payers and health tech evaluators. We’re looking at a new era of transparency and comparability ushered in by this new, publicly available specification.
Growing Importance in Market Access
The details of LCA standardization across the global pharmaceutical industry will need more time to be carved out completely. But already major health systems including NHS England, The National Institute for Health and Care Excellence, and the Norwegian Hospital Procurement Trust are increasingly looking at integrating environmental criteria into therapy evaluation and purchasing. As a result, therapies supported by credible LCA and PCF data can gain a competitive advantage in market access and tendering. (Tender, or tendering, refers to a formal process by which pharmaceutical therapies and healthcare technologies are procured.)
Consider the National Institute for Health and Care Excellence (NICE), which sits at the gateway to the UK public healthcare market. Its rigorous assessments of a health technology’s safety, clinical effectiveness, and affordability directly shape what the National Health Service (NHS) will fund. Now, NICE is exploring whether environmental impact evidence could join that submission, and whether it would be structured much like the clinical and cost-effectiveness data producers must submit as part of their market access bids. Their Health Technology Assessment (HTA) Innovation Laboratory is assessing what the evidence might look like, and looks to PAS 2090 as the standard that can provide a credible, consistent framework.
Healthcare payers are beginning to evaluate the environmental footprint of the therapies they buy. In crowded therapeutic categories, that creates an opening. Early adopters that showcase credible LCA and PCF data can differentiate their products and demonstrate the exact kind of leadership that resonates in a climate-conscious world. This is especially powerful for small- and medium-sized enterprises (SMEs) that can’t always win on price. Environmental performance gives them a different way to compete — one built on integrity and innovation rather than a race to the bottom on cost. And there’s now evidence that it works.
In a case study conducted with the Norwegian Hospital Procurement Trust (Sykehusinnkjøp), researchers found that prioritizing environmental criteria paid off in the long run through a more secure supply chain and a shift away from non-renewable materials. Rewarding environmental performance over price raised public spending in the short term, but it kept suppliers in the market and reduced medicine shortages over time. Most tellingly, in the Trust’s anti-infectives tender, environmental criteria brought suppliers back into contention — 8 of 21 contracts went to bids that were not the lowest priced. In other words, by showcasing their products’ reduced environmental impact along with assessments of supply chain risks and hotspots, some companies are returning with competitive bids that not too long ago may have had little hope of winning.
Operational and Supply Chain Benefits
LCAs also offer a number of benefits for improved business operations and overall supply chain efficiency. By pinpointing energy intensive steps and materials with disproportionate environmental impacts, LCAs provide companies with a better understanding of their critical supply chain vulnerabilities. And by tending to these hotspots strategically, organizations can reduce environmental risk, optimize performance, and lower long-term operational costs.
A few highlighted benefits coming from the use of LCA in support of pharmaceutical product development include:
- Process optimization, spotting materials and supply chain areas with outsized environmental impact.
- Minimizing waste and harmful emissions across the product’s life cycle for environmental and regulatory gains.
- Resource-efficient product design, resulting in lower material and energy use and decreased production costs.
- Enhanced supply chain resilience, as LCA insights help address process and supply chain vulnerabilities before they disrupt operations.
Future-proofing for 2030 and Beyond
A decade from now, environmental data won’t be a differentiator — it will be an expectation. Climate pressures and resource scarcity are already reshaping operational risk and cost, and global health systems are steadily raising the bar for the environmental evidence they require from suppliers.
Companies that adopt PAS 2090-aligned LCAs today are doing more than reducing impact. They’re future-proofing, building the transparency and market credibility that tomorrow’s industry will demand. The head start starts now.
Ready to Strengthen Your Environmental Strategy?
Our LCA experts help pharmaceutical companies and suppliers generate high quality, PAS 2090 aligned assessments that unlock strategic, operational, and market access advantages.
Contact us to get started with an LCA or PCF that elevates your sustainability and competitive position.
About the Author
Millicent Gabriel is a Life Cycle Associate and sustainability consultant with SCS Consulting Services, bridging life sciences and environmental stewardship. She holds an MS from Northeastern University in Cell and Tissue Engineering and a BS in Chemical Engineering. With a five-year background in the pharmaceutical sector, she combines expertise in Life Cycle Assessments (LCA) and Product Carbon Footprints (PCF) to help empower clients to make smart decisions for emission reductions. She also focuses on Extended Producer Responsibility (EPR) and end-of-life management of products and packaging.
DOHA, Qatar–(BUSINESS WIRE)–Doha Debates, de Qatar Foundation, estrenó una nueva temporada de Doha Debates Podcast, con 20 episodios que se publicarán semanalmente hasta el 16 de febrero de 2027. La serie reúne a destacados pensadores de todo el mundo para analizar algunos de los temas más complejos y relevantes de la actualidad. Los nuevos episodios profundizan en cuestiones planteadas en los principales debates y foros públicos de Doha Debates mediante conversaciones extensas y reflexivas.
EDISON, N.J.–(BUSINESS WIRE)– #CollaborativeSurgicalIntelligence–Redefine Surgery, a medical technology company building physical AI for surgery, today announced the closing of an oversubscribed pre-seed financing round, bringing total capital raised to $10 million. Backed predominantly by surgeon investors, the financing will support continued development of the company’s surgical intelligence platform as it advances toward commercialization. The financing announcement follows Wednesday’s announcement by Catalyst OrthoScience
NUEVA YORK–(BUSINESS WIRE)–Elliptic, líder mundial en el riesgo en cadena, lanzó hoy Pulse. Pulse pone la priorización de pistas sobre criptomonedas directamente en manos de cada agente de primera línea de las fuerzas de seguridad y del gobierno. Las criptomonedas ahora están presentes en todos los ámbitos de las fuerzas de seguridad, desde los agentes que patrullan las calles hasta el detective asignado a la investigación de un caso. Pulse le brinda a cada uno de ellos un resumen financiero
لندن–(BUSINESS WIRE)–أعلنت شركة HeadFirst Global، الرائدة في مجال تنظيم العمل، اليوم أنها ستصبح Vertage، حيث تقوم ببناء منصة تكنولوجية عالمية تقوم بتنسيق المزيج المناسب من المواهب الخبيرة ووكلاء الذكاء الاصطناعي بشكل ديناميكي لتحقيق نتائج العمل التي تحتاجها المؤسسات.يتناول هذا البيان الصحفي الوسائط المتعددة. يمكنك الاطلاع على البيان كاملاً هنا: https://www.businesswire.com/news/home/20260923352314/ar/Edzard Overbeek، الرئيس التنفيذي للمجموعة في Vertageتجمع المجموعة -التي تبلغ قيمتها 10 مليارات
LONDRA–(BUSINESS WIRE)–HeadFirst Global, un leader nel settore dell’orchestrazione del lavoro, oggi ha annunciato che diventerà Vertage, mentre sviluppa una piattaforma tecnologica globale in grado di selezionare dinamicamente la giusta combinazione ideale di talenti esperti e agenti IA per offrire alle aziende i risultati operativi di cui queste hanno bisogno. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono o
New research reveals a large “switchable middle” of banking customers who are only moderately satisfied at best with their primary financial institution
The Banking Expectation Gap – Global Edition
GRAND-LANCY, Switzerland, Sept. 24, 2026 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in banking technology, today announced new global research commissioned with Celent, “The Banking Expectation Gap: Global Consumer Edition”. The findings reveal that banks face a fight to keep three in four customers as expectations rise for more personalized, advisory and AI-enabled banking experiences. Despite this, just 4% of banks state that investment in personalization of the customer experience is their top priority.
The study shows that nearly three-quarters of global banking customers are only moderately satisfied or less than moderately satisfied with their primary financial institution, creating a large “switchable middle” open to switching for better value, stronger digital experiences and services that reflect their needs. Over half (53%) of global consumers are dissatisfied with their payment services and 39% cite dissatisfaction with security and fraud protection. One in four globally have recently considered switching their primary bank, while 56% of global retail banks say it has become more challenging to win and retain customers in the past year.
Personalization has emerged as a deciding factor in customer loyalty. More than half (58%) want more financial guidance, while 51% say their bank should better anticipate their needs when they open the app or call. Around 40% want rates or other benefits that reflect the size or length of their relationship with the bank. Together, these findings point to growing demand for banking experiences that feel more relevant, advisory and personalized across both digital and human-assisted channels.
At the same time, customers are increasingly open to AI-enabled engagement where it helps them better understand and manage their finances. More than two-thirds (68%) would use a conversational interface for banking queries, and younger cohorts show particularly strong interest in AI-powered personalized financial advice. There is less enthusiasm for AI features that take automated actions. Fewer than half of global consumers would “definitely use” AI features that manage purchases on their behalf or perform routine transactions such as bill payment. Trust remains critical: privacy and data security are the leading concerns about AI in banking, cited by 47%, followed by errors or inaccurate decisions at 36%.
Banks are making efforts to modernize services in response to these demands, with nearly half (46%) saying they plan to make major changes or fully replace core banking systems in 2027. More than a fifth (over 20%) expect to expand AI initiatives beyond internal operations and into direct customer-facing use cases.
Michael Bernard, Principal Banking Analyst, Celent, said: “Customers want banking that feels more personal, more secure and easier to use, while still providing human support when it matters. These expectations are rising just as AI is reshaping how customers engage with financial services, creating a new expectation gap between the experiences customers want and what many banks are currently able to deliver.”
William Moroney, Chief Revenue Officer, Temenos, said: “What influences customer loyalty has changed dramatically. To win the ‘switchable middle’, including the growing mass affluent market, banks need to deliver the trust, relevance and convenience customers now demand from every financial interaction. With modern technology foundations and responsible AI, banks can turn the Expectation Gap into an opportunity to deepen relationships and drive growth at scale.”
About the Research
Celent surveyed 2,515 global banking consumers aged 18–65+ in June, July, and August 2026. The study included respondents from Europe (29%), the United States (28%), Asia-Pacific (19%), Latin America (12%), and the Middle East and Africa (11%). Additional insights in this report are drawn from the Celent Dimensions Survey of 216 global banking leaders. Celent analysts also conducted in-depth one-on-one interviews with banking leaders, concentrated among banks with US$10B–$500B in assets.
To read the full report, The Banking Expectation Gap: Global Consumer Edition, please download it here: https://www.temenos.com/resource/the-banking-expectation-gap-global-edition/
Attachment
CONTACT: Scott Rowe Temenos + 44 (0) 20 7423 3857 scott.rowe@temenos.com
BERLIN–(BUSINESS WIRE)–（ビジネスワイヤ） — 超早期山火事検知のリーダーであるドライアド・ネットワークスは、アラスカで開催されたXプライズWildfireの自律型山火事対応部門の決勝でパフォーマンスが評価され、80万ドルの賞金を獲得しました。 ドライアドは、当初約300チームが参加した4年間におよぶコンテストを勝ち進みました。そして2026年6月、決勝に進出した3チームに、アラスカの原野1,000平方キロメートルを対象に、おとりとして設置された火を無視しつつ、危険度の高い山火事を自律的に検知して発火から10分以内に完全に消火するという課題が与えられました。これは、破壊的な火災が制御不能になる前に阻止するための必要事項を検証する、史上最も厳しい実地試験でした。 試験において、ドライアドのSilvanetセンサーネットワークは、おとりの火をすべて無視しつつ、対象の火災を12分以内に検知・確認して自律的に対応を開始することに成功しました。そして自律型のSilvaguard観測ドローンが状況把握のための情報を提供し、消火ドローンが火元に正確に消火剤を投下しました